High frequency chest compression (HFCC) offers a noninvasive therapeutic technique for a variety of thoracic region disorders. For more than 30 years, the HFCC focus has been on pulmonary disease. Significant pulmonary secretion enhancement and increased expectorated sputum output have been reported for cystic fibrosis (CF) patients with the application of HFCC therapy [1]. What follows describes certain capabilities of this well established pneumatically driven technique that is applicable to cardiovascular disease. HFCC can address a wide spectrum of health disorders, providing many cardiopulmonary benefits [2].

HFCC uses a pneumatically driven pump (source) and an inflatable vest, with a unique pump valve design, that can produce various pressure waveform shapes (trapezoidal, triangular, or sinusoidal) at the pump and vest locations [1,2]. The energy associated with those waveforms is transferred to the thoracic region for therapeutic purposes, including CF.

End of life for...

You do not currently have access to this content.